STOCK TITAN

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has announced its Q2 2024 corporate update and financial results conference call. The call is scheduled for August 13, 2024, at 4:30 PM ET. Participants can register online or dial in to join the call. For U.S. callers, the number is 1-833-316-0559, while international callers should use 1-412-317-5730. A live webcast will also be available. Replay options include a webcast replay and a telephonic replay accessible with specific access codes. This event provides an opportunity for investors and analysts to gain insights into BioCardia's recent performance and future outlook.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+5.95%
1 alert
+5.95% News Effect

On the day this news was published, BCDA gained 5.95%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2024 by conference call on Tuesday, August 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10191562/fd3d36338a. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=BLDb4kwc

A webcast replay of the call will be available approximately one hour after the end of the call at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6578627.

About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms.  For more information visit www.biocardia.com.


FAQ

When is BioCardia's Q2 2024 earnings call scheduled?

BioCardia's Q2 2024 earnings call is scheduled for Tuesday, August 13, 2024 at 4:30 PM ET.

How can investors participate in BioCardia's (BCDA) Q2 2024 conference call?

Investors can participate by registering online or by calling 1-833-316-0559 (U.S.) or 1-412-317-5730 (international). A live webcast will also be available.

Will there be a replay available for BioCardia's (BCDA) Q2 2024 earnings call?

Yes, a webcast replay will be available at https://services.choruscall.com/ccforms/replay.html, and a telephonic replay can be accessed using specific numbers and access code 6578627.

What is the focus of BioCardia's (BCDA) business?

BioCardia focuses on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases.
Biocardia Inc

NASDAQ:BCDA

BCDA Rankings

BCDA Latest News

BCDA Latest SEC Filings

BCDA Stock Data

13.37M
7.78M
18.98%
5.25%
3.61%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SUNNYVALE